Everbliss 5mg Tablet
Rx RequiredSalt Composition: Everolimus
Expiry Date: 01/2028
Buy at $104.95
Inclusive of all taxes
10 Tablet in a strip
About The Product
Kidney Cancer
Description
Everbliss 5mg Tablet is a doctor prescribed medicine that is used as an immunosuppressive and anticancer medication.It suppress the immune system to prevent organ transplant rejection and treat advanced cancers such as hormone receptor-positive breast cancer, advanced renal cell carcinoma, pancreatic neuroendocrine tumours, and certain brain tumours like sub ependymal giant cell astrocytoma.Everbliss 5mg Tablet contains Everolimus that suppress the immune response and helps to fight against cancer.
Common Side Effects
- Everbliss 5mg Tablet is an immunosuppressive and anticancer medication.Therefore,it has several common side effects like any other medicine.Consult your doctor, if side effects persist for longer period of time.
- ● Vomiting ● Nausea ● Muscle Cramps ● Abdominal Pain ● Diarrhea ● Rashes ● Cough ● Pneumonitis (lung inflammation) ● Severe infections ● Kidney failure ● Low blood cell counts ● Thrombotic microangiopathy ● Angioedema ● Pleural effusion.
Dosage And Administration
- Everbliss 5mg Tablet is administered orally with water , can be taken with or without food.
- Duration and Dosage of the capsule depends on the cancer type, its stage and overall health of the patient on doctor's guidance.
- Avoid breaking, chewing and biting of capsule for effective results.Consult your doctor for exact dosage.
Mechanism Of Action
Everbliss 5mg Tablet contains Everolimus that belong to the class of tyrosine kinase inhibitor class.
It inhibits mTOR kinase, a protein that regulates cell growth and proliferation, thereby suppressing immune responses in transplant patients and halting tumour cell division in cancers.
Faqs
The purpose of Everbliss 5mg Tablet is to suppress the immune system to prevent organ transplant rejection and treat advanced cancers such as hormone receptor-positive breast cancer, advanced renal cell carcinoma, pancreatic neuroendocrine tumours, and certain brain tumours like sub ependymal giant cell astrocytoma.
References
• Arena, C., Bizzoca, M. E., Caponio, V.
C. A., Troiano, G., Zhurakivska, K., Leuci, S., & Lo Muzio, L.
(2021). Everolimus therapy and side-effects: A systematic review and meta-analysis.
International Journal of Oncology, 59(1), 54. • Sánchez-Fructuoso, A. I.
(2008). Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials.
Expert Opinion on Drug Metabolism & Toxicology, 4(6), 807-819. • Houghton, P. J.
(2010). Everolimus.
Clinical cancer research, 16(5), 1368-1372. • Saran, U., Foti, M., & Dufour, J. F.
(2015). Cellular and molecular effects of the mTOR inhibitor everolimus.
Clinical science, 129(10), 895-914.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
